Understand the source comparison
TB-4 Research Deep Sleep Considerations: Research Protocol Comparison
Rodent model (2024, Frontiers in Neuroscience) 2 mg/kg SC, 3× weekly Early light cycle (inactive phase) 23% increase in SWS duration IL-6 ↓41%, IL-1β ↓38% Strongest evidence for TB-4's direct effect on sleep architecture via hypothalamic neuroinflammation redu
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rodent model (2024, Frontiers in Neuroscience)
- 2 mg/kg SC, 3× weekly
- Early light cycle (inactive phase)
- 23% increase in SWS duration
- IL-6 ↓41%, IL-1β ↓38%
- Strongest evidence for TB-4's direct effect on sleep architecture via hypothalamic neuroinflammation reduction. Mechanism is clear and reproducible
- Human pilot (2025, Sleep Medicine Reviews)
- 200 mg SC, weekly
- Morning (6–9 AM)
- 17% increase in SWS %, improved subjective quality
- hsCRP ↓22% at week 6
- Promising translation to human research, though sample size (n=18) limits generalisability. Timing may be critical for maximising SWS benefit
- Combination protocol (2025, unpublished)
- TB-4 150 mg weekly + DSIP 100 mcg nightly
- TB-4 morning, DSIP pre-sleep
- 31% increase in SWS vs TB-4 alone
- Not measured
- Suggests synergistic potential when targeting multiple sleep pathways, but requires controlled trials to isolate TB-4's independent contribution
- High-dose single administration (2023, rodent model)
- 10 mg/kg SC, single dose
- Mid-dark cycle (active phase)
- No significant SWS change vs placebo
- Transient ↓IL-6 at 24h, returned to baseline by 72h
- Single high-dose bolus insufficient for sustained microglial phenotype shift. Supports weekly repeat-dose protocols over infrequent high-dose approaches
- Emerging TB-4 research increasingly points to a narrow but reproducible sleep benefit: when chronic neuroinflammation disrupts hypothalamic sleep regulation, consistent anti-inflammatory peptide administration can restore slow-wave sleep architecture. At Real Peptides, precision matters. Every research-grade peptide undergoes small-batch synthesis with exact amino-acid sequencing to ensure reliability across protocols. If your research explores sleep-inflammation connections, sourcing peptides with verified purity and consistent bioactivity isn't optional. It's the baseline requirement for reproducible results.
- The TB-4 and sleep connection remains under active investigation, but the mechanistic framework is becoming clearer. It's not a universal sleep aid. It's a targeted intervention for one specific disruptor (neuroinflammation) in one specific brain region (hypothalamus). For research teams designing protocols around this mechanism, timing, dosing consistency, and subject screening for baseline inflammatory tone will determine whether results replicate or disappoint.